Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fatma Funkner"'
Autor:
Peter Wengenmayer, Carsten Weishaupt, Sebastian Ochsenreither, Birgit Scheel, Lucie Heinzerling, Tobias Seibel, Franz-Georg Bauernfeind, Gianluca Quintini, Beate Schmitt-Bormann, Marina Gonzalez, Juergen Krauss, Michael Fluck, Erika Richtig, Martin H. Falk, Ainara Soria, Jose Manuel Trigo Perez, Ulrike Gnad-Vogt, Honey Kumar Oberoi, Patrick Terheyden, Thomas Eigentler, Marc Oliva, Peter Mohr, Dominik Vahrenhorst, Paula Codó, Céleste Lebbé, Fatma Funkner
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A502-A502
BackgroundCV8102 is a non-coding, non-capped RNA complexed with a carrier peptide activating the innate (via TLR7/8, RIG-I) and adaptive immune system.1 2 An ongoing phase I trial is investigating the intratumoral (i.t.) administration of CV8102 in p
Autor:
Sarah-Katharina Kays, Tobias Seibel, Thomas Eigentler, Claudia Stosnach, Fatma Funkner, Regina Heidenreich, Peter Mohr, Birgit Scheel, Juergen Krauss, Ulrike Gnad-Vogt, Juergen C. Becker, Felix Kiecker, Ralf Gutzmer, Oliver Schoenborn-Kellenberger, Lucie Heinzerling, Angelika Daehling, Jutta Sylvina Schreiber, Benjamin Weide, Patrick Terheyden, Tanja Strack, Carsten Weishaupt, Ute Klinkhardt
Publikováno v:
Cancer Research. 79:LB-021
CV8102 comprises a single-stranded non-coding RNA complexed with a cationic peptide. It acts as an agonist to TLR-7/-8 and RIG-I (Ziegler 2018) to stimulate the innate and adaptive immune system. CV8102 was shown to induce an upregulation of inflamma
Autor:
Benjamin Weide, Lucie Heinzerling, Patrick Terheyden, Jürgen Krauss, Jutta Sylvina Schreiber, Peter Brossart, Peter Mohr, Franz G Bauernfeind, Michael Fluck, Carsten Weishaupt, Angelika Daehling, Claudia Stosnach, Jürgen C. Becker, Thomas Eigentler, Gianluca Quintini, Sebastian Ochsenreither, Sarah-Katharina Kays, Fatma Funkner, Anke Muth, Senta Ulrike Gnad-Vogt
Publikováno v:
Web of Science
3096 Background: CV8102 is a non-coding, non-capped RNA that activates the innate (via TLR7/8, RIG-I) and adaptive immunity dose-dependently. CV8102 injected intratumorally (i.t.), as a single agent or combined with systemic anti-PD-1 antibody (Ab) l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3f0367afb1e567ebe1fb8082f3824e
https://publons.com/wos-op/publon/34619263/
https://publons.com/wos-op/publon/34619263/